Robotic Prostatectomy for High-risk Prostate Cancer: Translating the Evidence into Lessons for Clinical Practice

2014 ◽  
Vol 65 (5) ◽  
pp. 928-930 ◽  
Author(s):  
Francesco Montorsi
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
High Risk ◽  
Robotic Prostatectomy ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

scholarly journals Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery

2014 ◽  
Vol 115 (3) ◽  
pp. 419-429 ◽  
Author(s):  
Ketan K. Badani ◽  
Darby J. Thompson ◽  
Gordon Brown ◽  
Daniel Holmes ◽  
Naveen Kella ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
High Risk ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

971 Safety of selective nerve sparing in high risk prostate cancer during robotic prostatectomy

2014 ◽  
Vol 13 (1) ◽  
pp. e971
Author(s):  
S.S. Samavedi ◽  
H. Abdul-Muhsin ◽  
P.S.K. Pigilam ◽  
K. Palmer ◽  
G. Ebra ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Robotic Prostatectomy ◽  
Nerve Sparing ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

Knowing what’s growing: Why ductal and intraductal prostate cancer matter

2020 ◽  
Vol 12 (533) ◽  
pp. eaaz0152 ◽  
Author(s):  
Mitchell G. Lawrence ◽  
Laura H. Porter ◽  
David Clouston ◽  
Declan G. Murphy ◽  
Mark Frydenberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
High Risk ◽  
Poor Prognosis ◽  
Ductal Adenocarcinoma ◽  
Preclinical Research ◽  
Preclinical Testing ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer ◽  
Common Malignancy

Prostate cancer is a common malignancy, but only some tumors are lethal. Accurately identifying these tumors will improve clinical practice and instruct research. Aggressive cancers often have distinctive pathologies, including intraductal carcinoma of the prostate (IDC-P) and ductal adenocarcinoma. Here, we review the importance of these pathologies because they are often overlooked, especially in genomics and preclinical testing. Pathology, genomics, and patient-derived models show that IDC-P and ductal adenocarcinoma accompany multiple markers of poor prognosis. Consequently, “knowing what is growing” will help translate preclinical research to pinpoint and treat high-risk prostate cancer in the clinic.

Sign in / Sign up

Export Citation Format

Share Document